Mercado mundial de tratamiento de la púrpura: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de tratamiento de la púrpura

En términos de un mercado de rápido crecimiento, se ha considerado el mercado del tratamiento de la púrpura y también se espera que crezca a un ritmo enorme. Existe una gran demanda seguida de un flujo continuo del mecanismo de la cadena de suministro en varias regiones del mundo para el tratamiento de la púrpura. Estas manchas de sangre son dolorosas y pueden aparecer a cualquier edad, por lo que su tratamiento está ganando popularidad.

Data Bridge Market Research analiza la tasa de crecimiento del mercado mundial de tratamiento de la púrpura en el período de pronóstico 2022-2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado seleccionado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología de los pacientes, análisis de la cartera de productos, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento de la púrpura

Definición de mercado

Purpura is also known as blood spots or skin haemorrhages. It is the type of condition in which purple-coloured spots formed on the skin, the spots are also visible on the organs or mucous membranes, that includes the membranes on the inside of the mouth. Purpura occurs when small blood vessels burst out causing blood clot formation under the skin. Purpura spots are usually benign, but may indicate a more serious medical condition, such as a blood clotting disorder.  

Global Purpura Treatment Market Dynamics

Drivers

• Increasing Government Regulations

Governmental initiatives and regulation such as Orphan drug act, U.S., the Orphan Drug Policy Therapeutic Goods Act and Regulations, Australia and the Orphan Drug Regulation, Japan are likely to boost the market during the forecast period. Moreover, increase in R&D expenses from major pharmaceutical companies to develop new treatment options for purpura further drives the market. This boosts the market growth.

• Growing Demand For Combination Therapies

The rising demand for combination therapies is expected to boost the market growth of the purpura treatment drugs. Studies showed that combination therapies have relatively lower side effects, and are cost-effective, and show higher response rates in patients. Some major combination therapies include rituximab and dexamethasone, corticosteroids and IVIG, TPO-RA (eltrombopag), and dexamethasone.

Opportunities

• Increased Partnerships and Collaborations

Major market players are focusing on to launch new products in untapped regions, partnerships, collaborations, and acquisitions are likely to boost the purpura therapy drug market during the forecast period. For instance, in August 2019, Intas Pharmaceuticals Ltd launched a generic version of romiplostim used for the treatment of chronic idiopathic thrombocytopenic purpura (ITP) in India. In 2018, Ablynx gained approval from European Commission to develop Cablivi, a nanobodoy-based medicine. The medicine is one-of-its-kind which, when combined with plasma exchange and immunosuppression, can decrease the time taken by the platelet count to return to normal. Ablynx can acquire a strong hold in the market against its rivals due to this approval. This creates more opportunity for the market growth.

• Increasing Demand for Retail Pharmacies

The increase in the number of drugs for purpura being that is delivered through retail pharmacies and the rise in the number of retail pharmacies in developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Side Effects of Treatments

There are various side-effects associated with the treatment options of purpura. Treatments such as Splenectomy have side effects such as bleeding, blood clots, bleeding, infection. Excessive use of corticosteroids can also lead to side effects such as vomiting, nausea and many others. Thus, this hampers the market growth.

• Lack of Medical Equipments

The growth of the purpura treatment market is likely to be hampered due to the non-availability of medical equipment followed by proper medication for the people who are suffering from the disease. This factor hampers the growth of the market.

This global purpura treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global purpura treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Purpura Treatment Market Scope

The global purpura treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Senile Purpura
• Idiopathic Thrombocytopenic Purpura
• Thrombotic Thrombocytopenic Purpura
• Understand Henoch-Schönlein Purpura
• Others

Treatment

• Medication
• Surgery
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Purpura Treatment Market Regional Analysis/Insights

The global purpura treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global purpura treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global purpura treatment market throughout the forecasted period due to presence of the generic manufacturer.

North America dominates the market due to the presence of key manufacture of the product and high demand of diseases specific treatment.

La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación del mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Además, se consideran la presencia y disponibilidad de marcas globales y los desafíos que enfrentan debido a la gran o escasa competencia de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales, al tiempo que se proporciona un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado global del tratamiento de la púrpura

El panorama competitivo del mercado global de tratamiento de la púrpura proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado global de tratamiento de la púrpura.

Los actores clave que operan en el mercado global de tratamiento de la púrpura incluyen:

• Pfizer Inc (Estados Unidos)
• F. Hoffmann-La Roche Ltd (Suiza)
• Mylan NV (Estados Unidos)
• Fresenius Kabi AG (Alemania)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Novartis AG (Suiza)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Compañía Bristol Myers Squibb (Estados Unidos)
• GSK Plc. (Reino Unido)
• Bayer AG (Alemania)
• Industrias farmacéuticas Sun Ltd (India)
• Novartis AG (Suiza)

SKU-55258